CAS Number75706-12-6
SynonymsN-(4-trifluoromethyl-phenyl)-5-methylisoxazole-4-carboxamide; Leflunomidum; 5-Methyl-N-[4-(trifluormethyl)phenyl]isoxazol-4-carboxamid; Leflunomide; Leflunomida; Arava; lefunamide; MFCD00867593; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; 5-méthyl-N-[4-(trifluorométhyl)phényl]isoxazole-4-carboxamide; 5-Methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; HWA 486; Leflunomid
Molecular FormulaC12H9F3N2O2
Molecular Weight270.21
Purity≥98 (TLC)%
Density1.4±0.1 g/cm3
Boiling Point289.3±40.0 °C at 760 mmHg
Melting Point166.5 °C
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 75706-12-6 |
| Catalog No. | 2A-9011143 |
| Chinese Name | 来氟米特 |
| Synonyms | N-(4-trifluoromethyl-phenyl)-5-methylisoxazole-4-carboxamide; Leflunomidum; 5-Methyl-N-[4-(trifluormethyl)phenyl]isoxazol-4-carboxamid; Leflunomide; Leflunomida; Arava; lefunamide; MFCD00867593; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; 5-méthyl-N-[4-(trifluorométhyl)phényl]isoxazole-4-carboxamide; 5-Methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; HWA 486; Leflunomid |
| Molecular Formula | C12H9F3N2O2 |
| Molecular Weight | 270.21 |
| Purity | ≥98 (TLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 289.3±40.0 °C at 760 mmHg |
| Melting Point | 166.5 °C |
| Appearance | powder |
| Water Solubility | Water solubility: insoluble; water solubility: 27 |
| Storage Condition | Store in an airtight container in a cool, dry plac |
| Application | Leflunomide is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase and has anti-rheumatic effects. |
| HTC | 2934999090 |
| PubChem ID | 24278516 |
| MDL Number | MFCD00867593 |
| SMILES | Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F |
| InChI | 1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18) |
| InChI Key | VHOGYURTWQBHIL-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352202 |
| Hazard Symbols | Transport |
| MSDS | msds/11143_1_75706_12_6.pdf |
| Bioactivity | Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase, and acts as a disease-modifying antirheumatic drug. Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Cancer In Vitro Leflunomide is actually a prodrug that has been shown to inhibit proliferation of mononuclear and T-cells. Leflunomide is an inhibitor of several protein tyrosine kinases, with IC50 values between 30 mM and 100 mM in vitro cellular and enzymatic assays[1]. Leflunomide is capable of inhibiting anti-CD3- and interleukin-2 (IL-2)-stimulated T cell proliferation. Leflunomide is able to inhibit p59fyn and p56lck activity in in vitro tyrosine kinase assays. Leflunomide also inhibits Ca2+ mobilization in Jurkat cells stimulated by anti-CD3 antibody but not in those stimulated by ionomycin. Leflunomide also inhibits distal events of anti-CD3 monoclonal antibody stimulation, namely, IL-2 production and IL-2 receptor expression on human T lymphocytes. Leflunomide also inhibits tyrosine phosphorylation in CTLL-4 cells stimulated by IL-2[2]. Leflunomide is an immunomodulatory drug that may exert its effects by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), which plays a key role in the de novo synthesis of the pyrimidine ribonucleotide uridine monophosphate (rUMP). Leflunomide prevents the expansion of activated and autoimmune lymphocytes by interfering with the cell cycle progression due to inadequate production of rUMP and utilizing mechanisms involving p53[3]. Kinase Assay DHODase activity is measured by the DCIP colorimetric assay. This is a coupled assay in which oxidation of DHO and subsequent reduction of ubiquinone are stoichiometrically equivalent to the reduction of DCIP. Reduction of DCIP is accompanied by a loss of absorbance at 610 nm (ε=21500 M/cm). The assay is performed in a 96-well microtiter plate at ambient temperature (ca. 25°C). Stock solutions of 10 mM leflunomide and A771726 are prepared in dimethyl sulfoxide (DMSO) and these are diluted with reaction buffer (100 mM Tris and 0.1 % Triton X-100, pH 8.0) to prepare working stocks of the inhibitors at varying concentrations. For each reaction, the well contained 10 nM DHODase, 68 μM DCIP, 0.16 mg/mL gelatin, the stated concentration of ubiquinone, 10 μL of an inhibitor working stock to give the stated final concentration, and reaction buffer. After a 5-min equilibration period, the reaction is initiated by addition of DHO to the stated final concentrations. The total volume of reaction mixture for each assay is 150 μL, and the final DMSO concentration is ≤ 0.01% (v/v). The reaction progress is followed by recording the loss of absorbance at 610 nm over a 10-min period (during which the velocity remained linear). Velocities are reported as the change in absorbance at 610 nm per minute, and each reported value is the average of three replicates. In experiments where the DHO or ubiquinone concentration is varied, the other substrate is held constant at 200 μM. To determine the inhibitor potency of leflunomide and A771726, the effects of varying concentrations of the two compounds on the initial velocity of the DHODase reaction is measured over a concentration range of 0.01−1.0 μM. In these experiments the DHO and ubiquinone concentrations are held constant at 200 and 100 μM, respectively. References [1]. Davis JP, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35(4):1270-3. [2]. Xu X, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem. 1995 May 26;270(21):12398-403. [3]. Fox RI, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999 Dec;93(3):198-208. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 289.3±40.0 °C at 760 mmHg Melting Point 163-168°C Molecular Formula C12H9F3N2O2 Molecular Weight 270.207 Flash Point 128.8±27.3 °C Exact Mass 270.061615 PSA 55.13000 LogP 1.95 Vapour Pressure 0.0±0.6 mmHg at 25°C Index of Refraction 1.541 InChIKey VHOGYURTWQBHIL-UHFFFAOYSA-N SMILES Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1 Storage condition 2-8°C |
| Use of | Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase, and acts as a disease-modifying antirheumatic drug. Properties Articles79 Name leflunomide Synonym More Synonyms Leflunomide Biological Activity Description Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase, and acts as a disease-modifying antirheumatic drug. Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Cancer References [1]. Davis JP, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35(4):1270-3. [2]. Xu X, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem. 1995 May 26;270(21):12398-403. [3]. Fox RI, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999 Dec;93(3):198-208. Chemical & Physical Properties Molecular Formula C12H9F3N2O2 Exact Mass 270.061615 PSA 55.13000 Index of Refraction 1.541 InChIKey VHOGYURTWQBHIL-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2811 International Dangerous Regulations for sea transport: 2811 International Dangerous Regulations for air transport: 2811 14.2 United Nations shipping name European Land Transport Dangerous Regulations: TOXIC SOLID, ORGANIC, N.O.S. (Leflunomide) IMDG Code: TOXIC SOLID, ORGANIC, N.O.S. (Leflunomide) International air transport hazard regulations: Toxic solid, organic, n.o.s. (Leflunomide) 14.3 Transport hazard categories European Land Transport Danger Regulations: 6.1 International Maritime Transport Danger Regulations: 6.1 International Air Transport Danger Regulations: 6.1 14.4 Package group European Land Transport Danger Regulations: III International Maritime Transport Danger Regulations: III International Air Transport Danger Regulations: III 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Lazabemide | 103878-84-8 | 2A-9011134 |
| L-Deoxyalliin | 21593-77-1 | 2A-9011138 |
| Lecirelin | 2A-302222 | 2A-9011139 |
| Ledazerol | 116795-97-2 | 2A-9011141 |
| Ledoxantrone | 113457-05-9 | 2A-9011142 |
| Lemildipine | 125729-29-5 | 2A-9011144 |
| Lenacil | 2164-08-1 | 2A-9011145 |
| Lenampicillin | 80734-02-7 | 2A-9011146 |
| Lentagran | 55512-33-9 | 2A-9011148 |
| Leonurus sibiricas extract | 2A-302232 | 2A-9011149 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS